Company intelligence / Profile preview
Sapreme Technologies
Utrecht, Netherlands
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Sapreme has demonstrated preclinical efficacy of its proprietary endosomal escape compound SPT001 enabling enhanced delivery and activity of RNA therapeutics such as ASOs and siRNAs. The lead program targeting Duchenne muscular dystrophy aims to be a best-in-class therapy for this fatal pediatric monogenic disease.
- Therapeutic areas
- Rare Diseases
- Modalities
- RNA therapeuticsAntisense oligonucleotides (ASOs)Small interfering RNAs (siRNAs)Phosphorodiamidate morpholino oligomers (PMOs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Sapreme Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sapreme Technologies.